Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTP Regimen B: LM11A-31 for Progressive Supranuclear Palsy
NCT07264283Phase 2Enrolling by invitation
- Start
- Jul 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LM11A-31 in progressive supranuclear palsy (PSP). Started Jul 2026; status: enrolling by invitation.
02
Drugs
LM11A-31
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT07264283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264283.